Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Chronic Lymphocytic Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Chronic Lymphocytic Leukemia. Browse Chronic Lymphocytic Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
141
Shown on this page
12
Current sort
Recently updated
Condition scope
Chronic Lymphocytic Leukemia
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Chronic Lymphocytic Leukemia studies are organized in the registry

CLL is registered together with small lymphocytic lymphoma (SLL) in many records — they are treated as one disease in study design — so listings often carry both names. Drug-class abbreviations, particularly BTK and BCL-2 inhibitor terms, appear directly in current titles.

Terms that often appear in related listings
SLL BTK inhibitor relapsed CLL venetoclax

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Chronic Lymphocytic Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 141 matching trials for Chronic Lymphocytic Leukemia.
Live ClinicalTrials.gov results.
Active filters: "BTK inhibitor" Clear condition filters
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Not yet recruiting Phase 2 Interventional

Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor

NCT07796373
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Nemtabrutinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Not yet recruiting Phase 2 Interventional

Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT07887061
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Tacabrutideg, Sonrotoclax, Obinutuzumab, Transthoracic Echocardiography Test, Biospecimen Collection, Computed Tomography, Multigated Acquisition Scan
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

NCT06043674
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter's Transformation
Interventions
Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
Drug
Lead sponsor
Christine Ryan
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT07557056
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Nemtabrutinib, Questionnaire Administration, Venetoclax
Procedure · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 3 Interventional

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

NCT07220187
View directory record Official record
Conditions
Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Pirtobrutinib, Positron Emission Tomography, Prednisone, Rituximab, Rituximab and Hyaluronidase Human, Survey Administration, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
62
States / cities
Irvine, California • Laguna Hills, California • Orange, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

NCT07508995
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
BGB-16673, BGB-11417
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Enrolling by invitation No phase listed Observational

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

NCT06211413
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Interventions
no intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Active, not recruiting Phase 2 Interventional

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05388006
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Durvalumab, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Positron Emission Tomography (PET), Computed Tomography
Drug · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

NCT06863402
View directory record Official record
Conditions
Richter Syndrome, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Nemtabrutinib, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
864
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
32
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 11:27 AM EDT

About this Chronic Lymphocytic Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Chronic Lymphocytic Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Chronic Lymphocytic Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Chronic Lymphocytic Leukemia.